Crossmark

Integrated muti-omics data and machine learning reveal CD151 as a key biomarker inducing chemoresistance in metabolic syndrome-related early-onset left-sided colorectal cancer

Crossref DOI link: https://doi.org/10.1007/s10142-025-01634-w

Published Online: 2025-06-09

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hou, Yingdong

Xia, Hubin

Xu, Chenshan

Yu, Yuhua

Ji, Chenghao

Ruan, Wenli

Kong, Wencheng

Zhou, Yifeng

Zhang, Xiaofeng
Funding

Funding for this research was provided by:

Zhejiang Province Medical and Health Science and Technology Plan Project (2021KY848)

Construction Fund of Medical Key Disciplines of Hangzhou (OO20190001)

Key R&D Program of Zhejiang Province (No. 2023C03054 and No. 2024C03048)
License Information

Text and Data Mining valid from 2025-06-09

Version of Record valid from 2025-06-09
More Information

Article History

Received: 4 April 2025

Revised: 24 May 2025

Accepted: 4 June 2025

First Online: 9 June 2025

Declarations

:

: Written informed consent was obtained from all participants. Ethical approval was granted by the Institutional Review Board of the Affiliated Hangzhou First People’s Hospital (Approval No. KY-2024466-01). The clinical trial number was not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below